The service provides integrated preclinical strategy and execution support for novel therapeutics, spanning indication selection and Target Product Profile definition, design and review of preclinical development plans, and strategic alignment of nonclinical work with regulatory and clinical objectives. Support typically covers design and oversight of in vitro and in vivo pharmacology and toxicology studies, IND‑enabling packages, and coordination with CMC activities to ensure that nonclinical and manufacturing workstreams progress coherently toward first‑in‑human trials. Engagement duration depends on scope and stage, ranging from short, targeted reviews of existing preclinical plans or data to longer-term support managing CRO activities, interpreting emerging results, and iterating the development strategy. The service is aimed at virtual and lean biotechs, academic spin‑outs, and investors or partners needing experienced, hands‑on input to turn promising biology into a defendable, execution‑ready preclinical plan. The goal is to help projects generate decision‑grade data, de‑risk IND preparation, and focus resources on studies that are essential both for regulatory acceptance and for future diligence by partners and investors. Activities typically include gap analyses of current preclinical packages, drafting or refining integrated preclinical roadmaps, designing and overseeing key in vitro and in vivo studies, managing CRO selection and interaction, interpreting study results, and supporting preparation for pre‑IND and IND meetings. Deliverables are usually provided as structured slide decks and written reports, complemented by regular video conferences and working sessions to refine strategy and adapt execution plans as data emerge. Support is delivered largely online through document exchange and virtual meetings, allowing rapid access to subject‑matter experts across pharmacology, toxicology, translational science, and regulatory affairs.